Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease

A Case Series

Christine Strippel, MD,* Anna Heidebreder, MD,* Andreas Schulte-Mecklenbeck, PhD,* Lisanne Korn, Tobias Warnecke, MD, Nico Melzer, MD, Heinz Wiendl, MD, Matthias Pawlowski, MD, PhD, Catharina C. Gross, PhD,† and Stjepana Kovac, MD, PhD†

Correspondence

Dr. Kovac
stjepana.kovac@ukmuenster.de

Neurol Neuroimmunol Neuroinflamm 2022;9:e1137. doi:10.1212/NXI.0000000000001137

Abstract

Background and Objectives

Despite detection of autoantibodies, anti-IgLON5 disease was historically considered a tau-associated neurodegenerative disease, with limited treatment options and detrimental consequences for the patients. Observations in increasing case numbers hint toward underlying inflammatory mechanisms that, early detection provided, open a valuable window of opportunity for therapeutic intervention. We aimed to further substantiate this view by studying the CSF of patients with anti-IgLON5.

Methods

We identified 11 patients with anti-IgLON5 from our database and compared clinical, MRI, and CSF findings with a cohort of 20 patients with progressive supranuclear palsy (PSP) (as a noninflammatory tauopathy) and 22 patients with functional neurologic disorder.

Results

Patients with anti-IgLON5 show inflammatory changes in routine CSF analysis, an increase in B-lymphocyte frequency, and the presence of plasma cells in comparison to the PSP-control group and functional neurologic disease controls. Patients with intrathecal plasma cells showed a clinical response to rituximab.

Discussion

Our findings indicate the importance of inflammatory mechanisms, in particular in early and acute anti-IgLON5 cases, which may support the use of immune-suppressive treatments in these cases. The main limitation of the study is the small number of cases due to the rarity of the disease.

*These authors contributed equally to this work as co-first authors.

†These authors contributed equally to this work as co-senior authors.

From the Department of Neurology with Institute of Translational Neurology (C.S., A.S.-M., L.K., T.W., H.W., M.P., C.C.G., S.K.), University of Münster, Germany; Department of Neurology (A.H.), Medical University Innsbruck, Austria; and Department of Neurology (N.M.), Medical Faculty, Heinrich-Heine University of Düsseldorf, Germany.

Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Table 1 Clinical Characteristics of Patients With Anti-IgLON5 Disease

No.	Age at sampling, y	Disease duration, y	Anti-IgLON5 titer, serum	Anti-IgLON5 titer CSF	Presenting complaint	Oculomotor symptoms	Bulbar symptoms	Sleep disorder	Cognitive dysfunction	Overall disease phenotype classification	Tumor	Treatment
1	76	2	1:1,000	n.d.	Dysphagia	–	+++	+	++	Bulbar	No	PLEX; MP
2	56	9	1:1,000	n.d.	Neuropathy	–	–	–	–	Neuropathy	No	MP; PLEX; AZA
3	49	3	1:3,200	1:100	Dysarthria and sleep disorder	–	+++	+++	+	Bulbar/sleep	No	PLEX; MP; RTX
4	57	2	1:100	1:3.2	Laryngeal spasms	+	+++	++	–	Bulbar	No	IA; MP; RTX
5	74	2	1:1,000	1:100	Hyper-/dyskinesia	++	++	+	+	Dyskinesia	No	IA; MP; PLEX
6	62	1	1:1,000	1:100	Dysphagia and sleep disorder	+	++	++	–	Sleep/bulbar	Yes (Neuroendocrine Tumor)	IA; MP
7	52	1	1:3,200	1:100	Dysphagia	+	+++	–	–	Bulbar	No	PLEX; MP; RTX
8	81	7	1:320	1:10	Neuropathy	+++	–	++	++	Ocular	No	PLEX; MP
9	68	5	1:1,000	1:100	Hyper-/dyskinesia and sleep disorder	+	+	+++	++	Sleep/dyskinesia	No	MP; PLEX; RTX
10	77	8	1:320	1:10 ^a	Dysphagia	–	+++	–	+	Bulbar	No	MP; PLEX
11	72	8	1:3,200	n.d.	Dysphagia	(+)	+++	(+)	+	Bulbar	No	PLEX; MP

Abbreviations: AZA = azathioprine; IA = immunoadsorption; MP = methyl prednisolone; n.d. = not done; PLEX = plasmapheresis; RTX = rituximab.
Symptom presentation: – not present; + mild; ++ moderate; +++ severe.
^a CSF titer in CSF analysis in the referring center and external laboratory.

Anti-IgLON5 disease is a multifaceted and heterogeneous disease presenting with sleep disorder, bulbar dysfunction, ocular symptoms, movement disorder, and cognitive dysfunction, defined by the presence of antibodies against the neuronal cell adhesion protein IgLON5.¹ Postmortem studies in 6 cases showed evidence of neuronal accumulation of hyperphosphorylated tau but no inflammatory changes.² Thus, it shares histopathologic features with neurodegenerative forms of tau pathology, including progressive supranuclear palsy (PSP).

Despite the absence of inflammatory changes in pathologic specimens, there is evidence of protein elevation with no signs of oligoclonal bands (OCBs) in patients with anti-IgLON5 disease³; however, detailed cellular CSF analyses are lacking. We characterized 11 patients with anti-IgLON5 disease combining clinical parameters and routine CSF analysis including detailed CSF flow cytometry and compare them with patients having PSP and a control group with functional neurologic disorders.

Methods

We retrospectively screened our clinical database for patients with anti-IgLON5 disease (eFigure 1, links.lww.com/NXI/A690) and age matched them with patients diagnosed with PSP, in whom

standard and flow cytometric CSF data were collected during routine clinical differential diagnostic processes following standardized procedures (eMethods, <http://links.lww.com/NXI/A690>). IgLON5 antibodies in serum or CSF were detected by EUROIMMUN commercial kit. CSF and blood samples were analyzed as described previously.⁴ Flow cytometric data of patients with anti-IgLON5 disease and PSP were compared with an age-matched control group of functional neurologic disorders without any signs of inflammatory or epileptic CNS disorder.

Standard Protocol Approvals, Registrations, and Patient Consents

Patients gave written informed consent for the use of the clinical data as part of research projects. Ethics approval was given by the ethics committee of the Medical Faculty of the University of Münster, Germany (AZ 2013 350-f-S).

Data Availability

Data are available from the corresponding author on reasonable request.

Results

Eleven patients with anti-IgLON5 disease were identified (Table 1), CSF analyses including immune profiling by flow

Table 2 Comparison of Conventional CSF Parameters

	Reference values	Functional disorder	IgLON5	PSP ^a	Significance anti-IgLON5 disease vs PSP	Significance anti-IgLON5 disease vs functional disorder
Cells/μL (IQR)	<5	0 (0–1)	4 (0–8)	0 (0–1)	0.0131	0.0094
Total protein, mg/L (IQR)	200–500	397 (344–461)	751 (579–1,148)	559 (382–707)	0.1446	<0.0001
Albumin, QAlb (IQR)	NA	4.95 (4.30–5.85)	9.70 (7.48–12.85)	6.30 (4.88–8.70)	0.0464	<0.0001
Blood-CSF-barrier impairment	No	0/22	6/10	5/20	0.0569	0.0003
Lactate, mmol/L (IQR)	<2.6	1.64 (1.52–1.79)	1.91 (1.78–2.38)	1.77 (1.62–2.05)	0.4430	0.0085
Glucose ratio (IQR)	NA	0.60 (0.50–0.70)	0.66 (0.45–0.75)	0.60 (0.53–0.67)	>0.9999	>0.9999
Quantitative synthesis (Reiber)						
QIgG (IQR)	NA	2.25 (1.90–2.73)	4.75 (3.75–6.68)	3.15 (2.05–4.08)	0.0289	<0.0001
IgG % positive	No	0/22	0/10	0/20	>0.9999	>0.9999
QIgA (IQR)	NA	1.00 (0.90–1.33)	3.30 (1.95–5.08)	1.85 (1.13–2.10)	0.0267	<0.0001
IgA % positive	No	0/22	0/10	0/20	>0.9999	>0.9999
QIgM (IQR)	NA	0.20 (0.18–0.33)	0.85 (0.48–1.80)	0.30 (0.20–0.50)	0.0307	0.0002
IgM % positive	No	0/22	1/10	0/20	0.1163	0.1127
Quantitative synthesis (OCB type 2 or 3)						
IgG % positive	No	0/22	1/10	0/20	0.1163	0.1127

Abbreviations: Ig = immunoglobulin; IQR = interquartile range; MDS = Movement Disorder Society; NA = not applicable; OCB = oligoclonal band; PSP = progressive supranuclear palsy.

^a PSP was diagnosed according to the MDS-PSP criteria⁸; 17 patients were diagnosed with probable PSP and 3 with possible PSP.

cytometry, were available in 10. The clinical phenotype was in line with the previous literature¹ with a predominance of a bulbar and sleep disorder–related phenotype. In only 1 case, we found a metastasis of a neuroendocrine tumor with low-grade of differentiation and unknown primary 2 years after diagnosis of anti-IgLON5 disease. All cases were therapy naive at the time of CSF analysis—except for 1 treated with azathioprine and 1 with immunoadsorption and steroid treatment 6 weeks before CSF sampling. Four patients later on received second-line treatment with rituximab (RTX) resulting in stabilization of symptoms. Compared with 20 patients with PSP, who were matched in age at presentation and onset of disease, as well as clinical severity measured with the mRS, brain atrophy was seen in both groups, but specific midbrain atrophy was restricted to PSP cases (eTable 1, links.lww.com/NXI/A690). In comparison to patients with functional disorders and PSP cases, patients with IgLON5 exhibited increased total protein levels compared with patients with a functional disorder (Table 2). Six of 10 patients displayed blood-CSF-barrier dysfunction indicated by CSF/serum albumin quotient, with 1 patient showing an intrathecal immunoglobulin G and another one an increased immunoglobulin M synthesis. Three of 10 patients with anti-IgLON5 showed a mild pleocytosis (Table 2;

Figure 1A). Immune profiling of CSF cells⁴ revealed increased frequencies of B lymphocytes and occurrence of plasma cells (Figure 1, B–D) suggesting a B cell–related pathology, whereas other immune cell subtypes were not specifically affected (eFigures 2–4, CSF, 5–7 blood). Four patients with increased CSF plasma cells at initial presentation received treatment with RTX later on in the disease course, which resulted in clinical stabilization of the disease.

Discussion

Our cohort of patients with anti-IgLON5 showed signs of inflammatory processes indicated by molecular markers and significant changes in the B-cell compartment with detection of plasma cells in some patients. These changes were not observed in patients having PSP. This observation suggests that the presence of an antibody is crucial in the disease process as suggested in in vitro studies.^{5,6} Comparable CSF studies in anti-IgLON5 disease are limited. A recent meta-analysis of routine CSF findings suggested that in anti-IgON5 disease, high levels of protein were observed in the absence of pleocytosis and OCBs.³ We were able to corroborate high

Figure 1 CSF Findings in Anti-IgLON5 Disease

(A) Cell count in CSF samples obtained from 22 controls without any sign of inflammatory CNS disorders (blue circles), 10 IgLON5 patients (red squares) and 20 PSP patients (violet triangles) as determined by Fuchs-Rosenthal chamber. (B) Representative dot plot from flow-cytometric analysis of CSF used to quantify CD19^{high}CD138^{neg} B cells and CD19^{low}CD138^{high} plasma cells. (C, D) Relative (left, closed symbols) and total (right, open symbols) levels of B cells (C) and plasma cells (D) in the CSF. Error bars indicate the median and interquartile range. Statistical analysis was done by Kruskal-Wallis test with Dunn's post-test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

protein levels and absence of OCBs in most patients. In our cohort, significant CSF pleocytosis was found in a subgroup of 3 patients. Second-line treatment with RTX was effective in halting disease progression as has been suggested in a previous review.⁷

Overall, our study illustrates that patients with anti-IgLON5 disease have inflammatory changes in the CSF. Therefore, the use of immune-modulatory therapies might be considered in these cases, but further studies are required to issue a general recommendation.

Study Funding

No targeted funding reported.

Disclosure

The authors declare no conflict of interests. Go to Neurology.org/NN for full disclosures.

Publication History

Received by *Neurology: Neuroimmunology & Neuroinflammation* August 23, 2021. Accepted in final form December 3, 2021.

Appendix Authors

Name	Location	Contribution
Christine Strippel, MD	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
Anna Heidebreder, MD	Department of Neurology, Medical University Innsbruck, Austria	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
Andreas Schulte-Mecklenbeck, PhD	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Study concept or design and analysis or interpretation of data
Lisanne Korn	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Major role in the acquisition of data

Appendix (continued)

Name	Location	Contribution
Tobias Warnecke, MD	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Analysis or interpretation of data
Nico Melzer, MD	Department of Neurology, Medical Faculty, Heinrich-Heine University of Düsseldorf, Germany	Drafting/revision of the manuscript for content, including medical writing for content, and study concept or design
Heinz Wiendl, MD	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Study concept or design
Matthias Pawlowski, MD, PhD	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Drafting/revision of the manuscript for content, including medical writing for content
Catharina C. Gross, MD	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
Stjepana Kovac, MD, PhD	Department of Neurology with Institute of Translational Neurology, University of Münster, Germany	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data

References

1. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. *Lancet Neurol*. 2014;13(6):575-586.
2. Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. *Acta Neuropathol*. 2016;132(4):531-543.
3. Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis—a systematic analysis. *Front Neurol*. 2019;10:804.
4. Gross CC, Schulte-Mecklenbeck A, Madireddy L, et al. Classification of neurological diseases using multi-dimensional cerebrospinal fluid analysis. *Brain J Neurol*. 2021;144(9):2625-2634.
5. Landa J, Gaig C, Plagumà J, et al. Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration. *Ann Neurol*. 2020;88(5):1023-1027.
6. Ryding M, Gamre M, Nissen MS, et al. Neurodegeneration induced by anti-IgLON5 antibodies studied in induced pluripotent stem cell-derived human neurons. *Cells*. 2021;10(4):837.
7. Cabezu-García P, Mena-Vázquez N, Estivill Torris G, Serrano-Castro P. Response to immunotherapy in anti-IgLON5 disease: a systematic review. *Acta Neurol Scand*. 2020;141(4):263-270.
8. Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society Criteria. *Mov Disord*. 2017;32(6):853-864.

Neurology[®] Neuroimmunology & Neuroinflammation

Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series

Christine Strippel, Anna Heidbreder, Andreas Schulte-Mecklenbeck, et al.
Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.0000000000001137

This information is current as of January 14, 2022

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/9/2/00.full.html
References	This article cites 8 articles, 0 of which you can access for free at: http://nn.neurology.org/content/9/2/00.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Immunology http://nn.neurology.org/cgi/collection/all_immunology Autoimmune diseases http://nn.neurology.org/cgi/collection/autoimmune_diseases
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.